Patent SG-11201901423X-A (SG)
Title: Amylin analogues
Inventor: MATHIESEN JESPER MOSOLFF
IPC: C07K14/575
Filed: 2017-09-11
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 March 2018 (15.03.2018) WIPO I PCT omit °nolo olo Hilo° mom° oimIE (10) International Publication Number WO 2018/046719 Al W O 20 18/0 467 19 Al (51) International Patent Classification: C07K 14/575 (2006.01) A61P 5/48 (2006.01) A61K 38/22 (2006.01) (21) International Application Number: PCT/EP2017/072718 (22) International Filing Date: 11 September 2017 (11.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 16188024.0 09 September 2016 (09.09.2016) EP (71) Applicants: ZEALAND PHARMA A/S [DK/DK]; Smedeland 36, 2600 Glostrup (DK). BOEHRINGER INGELHEIM INTERNATIONAL GMBH [DE/DE]; Binger Strasse 173, 55216 Ingelheim (DE). (72) Inventors: MATHIESEN, Jesper Mosolff; Brudedalen 26, 3520 Farum (DK). GIEHM, Lise; Radmand Steins Alle 29, 4th, 2000 Frederiksberg (DK). MUNCH, Henrik Ko- foed; Borgmester Fischers Vej 5C 3,3, 2000 Frederiksberg (DK). VILLADSEN, Jesper Skodborg; Klovertoften 15, 2740 Skovlunde (DK). HAMPRECHT, Dieter Wolfgang; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). HEIM- RIETHER, Alexander; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingelheim am Rhein (DE). FOSSATI, Giacomo; Boehringer Ingelheim GmbH, Corporate Patents, Binger Strasse 173, 55216 Ingel- heim am Rhein (DE). (74) Agent: FORREST, Graham et al.; Mewburn Ellis LLP, City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: AMYLIN ANALOGUES (57) : The present invention relates to amylin analogues and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including obesity, excess food intake and associated metabolic diseases such as diabetes. The analogues have good physical and chemical stability, good solubility, and a long duration of action, and are well suited for use in the form of a liquid formulation.